Citi says the CSL share price can rise 23% from here

One leading broker sees a lot of upside for this biotherapeutics giant.

| More on:
Woman in celebratory fist move looking at phone

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been having a subdued week.

After charging higher following its FY 2023 results release last week, the biotherapeutics company's shares have now given back the majority of its gains.

While this is disappointing, it could prove to be a great buying opportunity for investors if Citi is on the money with its recommendation.

What is Citi saying about the CSL share price?

According to a recent note, its analysts have a buy rating and a $325 price target on the company's shares.

Based on the current CSL share price of $263.85, this implies a potential upside of just over 23% for investors over the next 12 months.

The broker is also forecasting a modest 1.6% dividend yield in FY 2024, which boosts the total return to approximately 25%.

What did the broker say?

Citi was pleased with the company's results and guidance for FY 2024. It also highlights that immunoglobulins demand is expected to remain strong and that the CSL share price would be trading in line with its 10-year average multiple if it rose to the broker's price target. It explains:

The FY23 was as pre-announced and the FY24 NPATA guidance was maintained. The new information was 1) CSL expects Ig sales to grow at HSD over the long term, driven by PID, SID and CIDP despite the incoming competition from FcRns, 2) strong Ig sales growth is expected in FY24 (mid-teens vol. + MSD pricing), 3) disclosure of timeline and magnitude of the expected Ig yield improvement, 4) ~30% decline in capex in FY24.

CSL still expects Behring GM to recover to pre-covid levels in 3-5 years, with the improvements back-end weighted (FY26-28) and multi-faceted (lower cost per litre, new products, mix shift, yield improvements). We adjust our FY24-25e NPATA per share (Core EPS) by 0%/-3%. Our new TP of $325 (from $340) implies CSL should trade on an FY26 PE of ~26x, in-line with the 10-year average. Maintain Buy.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

ASX shares Business man marking buy on board and underlining it
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man looks surprised as a woman whispers in his ear.
Broker Notes

These ASX 200 shares could rise 20% to 40%

Analysts are tipping these shares to deliver market-beating returns over the next 12 months.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Leading broker upgrades Pro Medicus shares to buy rating

Analysts at Bell Potter think this tech stock is a top buy right now.

Read more »

A woman in a bright yellow jumper looks happily at her yellow piggy bank representing bank dividends and in particular the CBA dividend
Broker Notes

3 reasons to buy Woolworths shares this month

Goldman Sachs thinks that now is the time to buy this retail giant.

Read more »

Investor sitting in front of multiple screens watching share prices
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Broker Notes

Beginner investors: 3 top Australian shares to buy for 2025

Analysts think these shares are buys and offer plenty of upside.

Read more »